Author

H. Melo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Alvarez-Quilon· 3 shared D. Durocher· 3 shared A. Veloso· 2 shared G. Martino· 2 shared J. Desjardins· 2 shared J. T. F. Young· 2 shared M. Zinda· 2 shared N. Chaudhary· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Alvarez-Quilon

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A semiconductor 96-microplate platform for real-time impedance-based high-throughput screening

S. Chitale, W. Wu, A. Mukherjee, H. Lannon, P. Suresh, I. Nag, C. Ambrosi, R. A. Gertner, H. Melo, B. Powers, H. Wilkins, H. Hinton, M. Cheah, Z. Boynton, A. Alexeyev, , J. Abbott

This paper introduces a semiconductor microplate platform for real-time impedance-based high-throughput screening, demonstrating its ability to profile compound mechanisms of action across diverse cell types.

bioRxiv · Jun 1, 2023Bioengineering

CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition

D. Gallo, J. T. F. Young, J. Fourtounis, G. Martino, A. Alvarez-Quilon, C. Bernier, N. M. Duffy, R. Papp, A. Roulston, R. Stocco, J. Szychowski, A. Veloso, H. Alam, P. S. Baruah, A. Bonneau Fortin, , D. Durocher

The paper identifies PKMYT1 as a therapeutic target for CCNE1-amplified cancers, showing that its inhibition leads to synthetic lethality and tumor regression in combination with gemcitabine.

bioRxiv · Apr 8, 2021Cancer Biology

CIP2A is a prime synthetic-lethal target for BRCA-mutated cancers

S. Adam, S. E. Rossi, N. Moatti, M. De Marco Zompit, T. F. Ng, A. Alvarez-Quilon, J. Desjardins, V. Bhaskaran, G. Martino, D. Setiaputra, S. M. Noordermeer, T. K. Ohsumi, N. Hustedt, R. K. Szilard, N. Chaudhary, , D. Durocher

The paper identifies CIP2A as a synthetic-lethal target in BRCA-mutated cancers by showing its essential role in mitotic chromosome stability and its interaction with TOPBP1.

bioRxiv · Feb 8, 2021 · PreprintCancer Biology

Designing Peptides on a Quantum Computer

V. K. Mulligan, H. Melo, H. I. Merritt, S. Slocum, B. D. Weitzner, A. M. Watkins, P. D. Renfrew, C. Pelissier, P. S. Arora, R. Bonneau

This paper maps protein design to a quantum annealer, demonstrating real-world applicability of quantum computing in designing peptides comparable to classical methods.

bioRxiv · Mar 11, 2020 · PreprintBioengineering

A genetic map of the response to DNA damage in human cells

M. Olivieri, T. Cho, A. Alvarez-Quilon, K. Li, M. J. Schellenberg, M. Zimmermann, N. Hustedt, S. E. Rossi, S. Adam, H. Melo, A. M. Heijink, G. Sastre-Moreno, N. Moatti, R. Szilard, A. McEwan, , D. Durocher

The paper identifies 840 genes involved in the DNA damage response through CRISPR/Cas9 screens and highlights specific gene functions in DNA repair and toxicity mechanisms.

bioRxiv · Nov 18, 2019Cancer Biology